Pharmacologic Pearls for End-of-Life Care

Am Fam Physician. 2009 Jun 15;79(12):1059-1065.

  Related Editorial

  Patient information: See related handout on care for people with a severe or complicated illness, written by the authors of this article.

As death approaches, a gradual shift in emphasis from curative and life prolonging therapies toward palliative therapies can relieve significant medical burdens and maintain a patient's dignity and comfort. Pain and dyspnea are treated based on severity, with stepped interventions, primarily opioids. Common adverse effects of opioids, such as constipation, must be treated proactively; other adverse effects, such as nausea and mental status changes, usually dissipate with time. Parenteral methylnaltrexone can be considered for intractable cases of opioid bowel dysfunction. Tumor-related bowel obstruction can be managed with corticosteroids and octreotide. Therapy for nausea and vomiting should be targeted to the underlying cause; low-dose haloperidol is often effective. Delirium should be prevented with normalization of environment or managed medically. Excessive respiratory secretions can be treated with reassurance and, if necessary, drying of secretions to prevent the phenomenon called the “death rattle.” There is always something more that can be done for comfort, no matter how dire a situation appears to be. Good management of physical symptoms allows patients and loved ones the space to work out unfinished emotional, psychological, and spiritual issues, and, thereby, the opportunity to find affirmation at life's end.

The aging population calls for an increasing emphasis on palliative care (interdisciplinary care that focuses on quality of life in the context of advanced, complex, and severe illness). This recently recognized medical subspecialty includes hospice as a subset of care focused on the latter few months of life. Palliative care is delivered across the continuum of care from office to hospital, nursing home, and home hospice. As death approaches, a gradual shift in emphasis from curative and life prolonging therapies toward palliative therapies can relieve significant medical burdens and maintain a patient's dignity and comfort. Pharmacologic symptom management can improve the quality of life of patients with a severe life-limiting illness. This article is intended as a primer on pharmacologic symptom management. More comprehensive sets of recommendations for end-of-life care can be found at the End of Life/Palliative Education Resource Center (http://www.eperc.mcw.edu/ff_index.htm) and the National Cancer Institute (http://www.cancer.gov/cancertopics/pdq/supportivecare), as well as in recent reviews.14

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References Comments

Opioids should be used for dyspnea at the end of life.

A

6, 7

Multiple studies have shown that nebulized opioids have no benefit over systemic administration in terms of effect or adverse effects.

Opioids should be used for pain at the end of life.

C

12

The ethical limitations of withholding opioids have limited the study of opioids versus placebo, except in neuropathic pain.

Stimulant laxatives are effective for prevention and treatment of constipation in persons on opioids.

C

20, 25

There is no clear benefit of one regimen over another.

Methylnaltrexone (Relistor) can be used for treatment of opioid bowel dysfunction.

B

22, 23

Methylnaltrexone has recently been added as a treatment option.

Corticosteroids can be used for malignant bowel obstruction.

B

33

Haloperidol (formerly Haldol) is effective for nausea and vomiting.

B

34, 35

Hyoscyamine (Levsin) should be used for the “death rattle” (excessive respiratory secretions).

C

40


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References Comments

Opioids should be used for dyspnea at the end of life.

A

6, 7

Multiple studies have shown that nebulized opioids have no benefit over systemic administration in terms of effect or adverse effects.

Opioids should be used for pain at the end of life.

C

12

The ethical limitations of withholding opioids have limited the study of opioids versus placebo, except in neuropathic pain.

Stimulant laxatives are effective for prevention and treatment of constipation in persons on opioids.

C

20, 25

There is no clear benefit of one regimen over another.

Methylnaltrexone (Relistor) can be used for treatment of opioid bowel dysfunction.

B

22, 23

Methylnaltrexone has recently been added as a treatment option.

Corticosteroids can be used for malignant bowel obstruction.

B

33

Haloperidol (formerly Haldol) is effective for nausea and vomiting.

B

34, 35

Hyoscyamine (Levsin) should be used for the “death rattle” (excessive respiratory secretions).

C

40


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Pharmacotherapy is only one component of end-of-life care. Quality palliative care is delivered by a team of caregivers and focuses on careful individualization of holistic care based on patient and family goals. The evidence base supporting interventions at the end of life is limited, but growing.

Symptom Management at the End of Life

Symptoms are often best controlled by elucidating and treating their causes. However, any intervention should be consistent with the patient's preferences and goals, especially in the context of palliative care. If test results cannot possibly lead to a change in management, the test is not indicated. Medical management of symptoms should follow the palliative care principles to start low and go slow, and treat to effect or adverse effect, recognizing the risks of polypharmacy.5

PAIN AND DYSPNEA

Pain and dyspnea are treated based on severity, with stepped interventions, primarily opioids. Dyspnea that persists despite optimal respiratory treatment is sensed in the same central nervous system structures as pain and should be considered as if it were “lung pain.” Moderate to severe dyspnea and pain may be treated with oral or parenteral opioids.1,6,7 Proven nonpharmacologic strategies should be optimized.8 Using one of many validated scales, physicians can support patients' efforts to set realistic goals for function and pain or dyspnea levels. Recommended scales should include assessment of intensity and quality of pain, as well as function.

Scales that include a nonverbal 0 to 10 line, faces scales, and intensity descriptive scales have proven reliable in persons with Mini-Mental State Examination scores averaging as low as 15.3 out of 30.9  For nonverbal patients, other scales, such as the Pain Assessment in Advanced Dementia scale, are necessary (Table 1).10

Table 1

Pain Assessment in Advanced Dementia Scale

Item 0 1 2 Score

Breathing independent of vocalization

Normal

Occasional labored breathing; short period of hyperventilation

Noisy, labored breathing; long period of hyperventilation; Cheyne-Stokes respiration

Negative vocalization

None

Occasional moan or groan; low level speech with a negative or disapproving quality

Repeated troubled calling out; loud moaning or groaning; crying

Facial expression

Smiling or inexpressive

Sad; frightened; frowned

Facial grimacing

Body language

Relaxed

Tense; distressed pacing; fidgeting

Rigid; fists clenched; knees pulled up; pulling or pushing away; striking out

Consolability

No need to console

Distracted or reassured by voice or touch

Unable to console, distract, or reassure

Total:*_____________


*— Total scores range from 0 to 10, with a higher score indicating more severe pain (0 = no pain to 10 = severe pain).

Adapted with permission from Warden V, Hurley AC, Volicer I. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):14.

Table 1   Pain Assessment in Advanced Dementia Scale

View Table

Table 1

Pain Assessment in Advanced Dementia Scale

Item 0 1 2 Score

Breathing independent of vocalization

Normal

Occasional labored breathing; short period of hyperventilation

Noisy, labored breathing; long period of hyperventilation; Cheyne-Stokes respiration

Negative vocalization

None

Occasional moan or groan; low level speech with a negative or disapproving quality

Repeated troubled calling out; loud moaning or groaning; crying

Facial expression

Smiling or inexpressive

Sad; frightened; frowned

Facial grimacing

Body language

Relaxed

Tense; distressed pacing; fidgeting

Rigid; fists clenched; knees pulled up; pulling or pushing away; striking out

Consolability

No need to console

Distracted or reassured by voice or touch

Unable to console, distract, or reassure

Total:*_____________


*— Total scores range from 0 to 10, with a higher score indicating more severe pain (0 = no pain to 10 = severe pain).

Adapted with permission from Warden V, Hurley AC, Volicer I. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):14.

Nonopioid pain therapies should be optimized; non-steroidal anti-inflammatory drugs, steroids, and bisphosphonates are particularly effective for bone pain.1,4,6 A variety of medications are also available for neuropathic pain, a subject beyond the scope of this article.

The fear that opioids will hasten death is an inappropriate barrier to their use, assuming proper dose initiation and escalation are used.11 Opioids are a central part of pain treatment in palliative care, including treatment of nonmalignant and neuropathic pain.12 Titration for effective pain management should be rapid and consistent, using parenteral or oral short-acting medications, with dosing intervals set according to peak effects rather than duration of action.13

Breakthrough dosing must be proportionate to the total 24-hour dose of opioids. It should be 10 to 20 percent of the 24-hour oral morphine equivalent (or 50 to 150 percent of the hourly intravenous rate). A common error is the administration of 5 to 10 mg of oxycodone (Roxicodone) for breakthrough pain when a patient is tolerating high long-acting doses. For example, if a patient requires 1,000 mg of oral morphine equivalent every 24 hours, the appropriate breakthrough dose would be 60 to 120 mg of oxycodone. Breakthrough doses should treat unpredictable spikes in pain and prevent breakthrough pain when predictable, such as before necessary turning or transfers. Increases in the basal dose should be 25 to 50 percent for mild to moderate pain and 50 to 100 percent for severe pain. To control symptoms, breakthrough doses should be administered each time an increase in a basal dose is initiated. Preparations that combine an opioid with acetaminophen, aspirin, or ibuprofen should be avoided because of the risk of toxicity above established dose ceilings of the nonopioid.14

Many patients with terminal illnesses and their families are reluctant to begin opioid therapy because of the stigma associated with addiction. Preparatory reassurance, education of the patient and family, and use of the term “opioids” instead of “narcotics” helps. If a persistent objection is raised to initiating one opioid, another can be substituted. Failure of one opioid at the highest tolerated dose may be treated by rotation to another opioid. Reduce dose equivalents by 50 to 75 percent when rotating opioids in the context of well-controlled pain to compensate for incomplete cross-tolerance. Dose ceilings of opioids are variable and often high. Methadone is among the most difficult and dangerous to use, but has advantages in cost and effectiveness. Physicians should consider consultation with a palliative care specialist before using methadone, unless they are familiar with its interactions, variable duration of effect, adverse effects, unique comparative potency with morphine, and risk of toxicity, including QT interval prolongation. The New Hampshire Hospice and Palliative Care Organization's opioid use guidelines (http://www.nhhpco.org/opioid.htm) provide a quick reference card that reviews opioid management and includes equianalgesic tables, opioid rotation guidelines, and a methadone and morphine nomogram.13

Common causes of a partial response or lack of response to opioids include: neuropathic pain; social, psychological, or spiritual pain; substance use disorders; and misinterpretation of symptoms for pain, particularly in persons who are cognitively impaired.

Sometimes, aggressive therapies for pain control, such as surgery, radiation, regional nerve blocks, and intra-spinal or epidural delivery devices, are appropriate and necessary when basic measures fail and interventions are consistent with patient goals.

Throughout treatment, physicians must evaluate the “total pain syndrome” and align treatment with the causes of pain as much as possible, optimizing psychological, social, and spiritual treatments and avoiding inappropriate pharmacologic management of psychosocial or spiritual pain.

OPIOID ADVERSE EFFECTS

Nausea and vomiting, sedation, and mental status changes are common with opioid initiation and most often fade within a few days. When initiating an opioid, prophylactic use of an antiemetic for three to five days can be effective in the susceptible patient.15 Persistent nausea and vomiting is related to chemoreceptor trigger zone stimulation, and can be treated with a combination of dose reduction, opioid rotation, and antiemetics.16 Undesirable sedation can be addressed with low-dose methylphenidate (Ritalin), which can be rapidly tapered when no longer needed.17 Allergy to opioids usually amounts to nothing more than sedation or gastrointestinal adverse effects, and can be managed expectantly. Localized urticaria or erythema at the site of an injection of morphine is caused by local histamine release and is not necessarily a sign of systemic allergy.

Constipation is one adverse effect of opioids that does not extinguish with time (Table 2).18 An important principle of pain management is that, when writing opioid prescriptions, physicians also need to write orders for the bowel preparation. Increasing fiber or adding detergents (e.g., forms of docusate) is not sufficient. Like pain, constipation is more easily prevented than treated. Start a conventional combination of a stimulant laxative with a stool softener (e.g., senna with docusate) or osmotic agent (e.g., polyethylene glycol solution [Miralax]) at the same time as the opioid.19 There is no good evidence of superiority of any one regimen over another.20 Polyethylene glycol solutions are easy to titrate, with no maximal dose; can be given once daily; and are particularly effective with the addition of a stimulant, such as senna. With increases in opioid dose, or with other risks of worsening constipation (e.g., change in environment, declining performance status), the laxative dose should be doubled or therapy stepped up by adding a stronger agent. Dosing can be ordered with the notation “hold for diarrhea” or a stepped action plan can be developed based on consistency and frequency of stool. Overflow diarrhea can occur with fecal impaction. Patients nearing death decrease their intake of solids, which is often expected to cause the cessation of bowel movements. However, 70 percent of the dry weight of stool consists of bacteria, so bowel activity can and should be maintained for comfort.21

Table 2

Treatment of Constipation in Patients Receiving Opioids

Treatment Dosage

Lactulose

15 to 30 mL orally two or three times per day

Magnesium hydroxide

30 to 60 mL orally at bedtime

Polyethylene glycol (Miralax)

One or more tablespoons dissolved in 4 to 8 oz of fluid orally per day

Senna with docusate

One to two tablets orally two to four times per day


Information from reference 18.

Table 2   Treatment of Constipation in Patients Receiving Opioids

View Table

Table 2

Treatment of Constipation in Patients Receiving Opioids

Treatment Dosage

Lactulose

15 to 30 mL orally two or three times per day

Magnesium hydroxide

30 to 60 mL orally at bedtime

Polyethylene glycol (Miralax)

One or more tablespoons dissolved in 4 to 8 oz of fluid orally per day

Senna with docusate

One to two tablets orally two to four times per day


Information from reference 18.

Opioid bowel dysfunction that is unresponsive to aggressive conventional medications, removal of anti-cholinergic or other contributing medications, enemas, opioid dose rotation, and opioid reduction may be carefully treated with methylnaltrexone (Relistor).22 It reverses muopioid receptor-mediated bowel paralysis without crossing the blood-brain barrier. In a recent industry-sponsored phase 3 trial, subcutaneous methylnaltrexone at 0.15 mg per kg led to a bowel movement within four hours in 48 percent of terminally ill patients with opioid bowel dysfunction versus 15 percent with placebo, with a median time of 45 minutes to first bowel movement versus 6.3 hours with placebo.23 A more recent study found a dose of 5 mg to be effective, but did not find a dose response above 5 mg.24 Methylnaltrexone is approved by the U.S. Food and Drug Administration for this indication.

Toxic effects of opioids at higher dose ranges or with rapidly escalating doses include forms of neuroexcitation, such as hyperalgesia, delirium, and myoclonus.25 A common pitfall is to confuse these symptoms with worsening pain and further escalate the dose, which may worsen neuroexcitation and increase hyperalgesia, thereby exacerbating total pain. Opioid reduction or rotation, with the addition of adjuncts for pain control, is indicated instead. Ketamine (Ketalar) can be an effective adjunct in severe cases, but requires experience or consultation.26

Unintentional overdose of an opioid can usually be managed expectantly; however, if partial reversal is necessary, very low-dose naloxone (formerly Narcan) can be quickly administered by giving 0.01- to 0.04-mg (or 1.5 mcg per kg) intravenous or intramuscular boluses every three to five minutes, titrated to respiratory rate or mental status (mix one 0.4 mg per mL ampule of naloxone with saline to make 10 mL, which equals 0.04 mg per mL).27 Continued close monitoring is necessary because duration of opioid effect may outlast naloxone.

BOWEL OBSTRUCTION, NAUSEA, AND VOMITING

Mechanical bowel obstruction is commonly associated with ovarian28 and colon cancers.29 If this cause is known or suspected, it is acceptable to opt not to proceed to invasive intervention urgently.30 Surgery or venting gastrostomy tube insertion should be undertaken only after careful consideration, because of potential procedural complications, lack of evidence for life prolongation, and recurrence rates up to 50 percent.31 Endoscopic bowel stenting can be a reasonable option for esophageal or duodenal obstruction. Standard conservative therapies may include cessation of oral intake, transient nasogastric suction, antiemetics, octreotide (Sandostatin), and corticosteroids. Octreotide inhibits the accumulation of intraluminal intestinal fluid and can be administered subcutaneously or intravenously at 50 to 100 mcg every six to eight hours and titrated rapidly to effect.32 It is also available in an intramuscular depot form, but this form costs more. Dexamethasone six to 16 mg intravenously daily may resolve a bowel obstruction caused by edema from gastrointestinal or ovarian cancer.33 Although there is no change in mortality at one month, a review of 10 trials confirmed that corticosteroids shrink swelling around the tumor and can allow resumption of oral intake with reinstatement of normal bowel activity (number needed to treat = 6).33 Tapering off corticosteroids should not be undertaken in this circumstance unless indicated for other reasons.

Persistent nausea and vomiting (without bowel obstruction) should be carefully investigated and treatment directed to the underlying cause, most commonly in the central nervous system or the gastrointestinal tract (Tables 3 and 4).34 If one medication fails, substitute another drug from a different class. Promethazine (Phenergan), a sedating antihistamine, is relatively ineffective in palliative care and is overused. As noted in a comprehensive review,34 off-label use of haloperidol (formerly Haldol), a low-cost antiemetic, can be at least as effective as ondansetron (Zofran).35 It is best used at lower doses than for psychosis and can be combined with other interventions.

Table 3

Antiemetics Used in Palliative Care by Category

Category Action Drug examples

5-HT3 receptor antagonists

Block serotonin receptors in the CNS associated with chemoreceptor trigger zone and “vomiting center”

Ondansetron (Zofran) 4 to 8 mg orally or IV every four to eight hours

Granisetron (Kytril) 1 mg orally or IV twice daily

Anticholinergics

Block acetylcholine receptors, slow bowel function, dry secretions

Scopolamine one to two patches (1.5 mg) applied topically and changed every 48 to 72 hours

Antihistamines

Block histamine release, have anticholinergic properties

Diphenhydramine (Benadryl) 12.5 to 50 mg orally, rectally, or IV every four to 12 hours

Promethazine (Phenergan) 25 to 50 mg orally, rectally, or IV every six hours

Benzodiazepines

CNS anxiolytic effects; enhances gamma-aminobutyric acid action, slowing neuronal function

Lorazepam (Ativan) 0.5 to 2 mg orally or IV every six hours

Cannabinoids

Brainstem cannabinoid receptor agonists, CNS anxiolytic effects

Nabilone (Cesamet) 1 to 2 mg orally every 12 hours

Dronabinol (Marinol) 5 to 10 mg orally, rectally, or under the tongue every six to eight hours

Marijuana (only where legal for medical use)

Corticosteroids

Anti-inflammatory, reduces tumor-related swelling centrally or peripherally

Dexamethasone 2 to 8 mg orally or IV every four to eight hours

Dopamine receptor blockers

Benzamides

Peripheral (more than central) dopamine D2 receptor blocker, with some 5-HT antagonism and cholinergic stimulation at bowel level improving gastric emptying and increasing lower esophageal sphincter tone

Metoclopramide (Reglan) 5 to 20 mg orally or IV every six hours as needed

Butyrophenones

Central (more than peripheral) dopamine D2 receptor blocker, with antimuscarinic activity

Haloperidol (formerly Haldol) 0.5 to 2 mg orally or IV every four to eight hours

Droperidol 1.25 to 2.5 mg IV (one to three doses)

Phenothiazines

Dopamine D2 receptor blocker, with some antimuscarinic and antihistaminic activity

Prochlorperazine (formerly Compazine) 5 to 10 mg orally or IV every six to eight hours; or 25 mg rectally every 12 hours

Chlorpromazine 12.5 to 25 mg IV every six to eight hours; or 25 to 50 mg orally every eight hours


5-HT = 5-hydroxytryptamine; CNS = central nervous system; IV = intravenously.

Information from reference 34.

Table 3   Antiemetics Used in Palliative Care by Category

View Table

Table 3

Antiemetics Used in Palliative Care by Category

Category Action Drug examples

5-HT3 receptor antagonists

Block serotonin receptors in the CNS associated with chemoreceptor trigger zone and “vomiting center”

Ondansetron (Zofran) 4 to 8 mg orally or IV every four to eight hours

Granisetron (Kytril) 1 mg orally or IV twice daily

Anticholinergics

Block acetylcholine receptors, slow bowel function, dry secretions

Scopolamine one to two patches (1.5 mg) applied topically and changed every 48 to 72 hours

Antihistamines

Block histamine release, have anticholinergic properties

Diphenhydramine (Benadryl) 12.5 to 50 mg orally, rectally, or IV every four to 12 hours

Promethazine (Phenergan) 25 to 50 mg orally, rectally, or IV every six hours

Benzodiazepines

CNS anxiolytic effects; enhances gamma-aminobutyric acid action, slowing neuronal function

Lorazepam (Ativan) 0.5 to 2 mg orally or IV every six hours

Cannabinoids

Brainstem cannabinoid receptor agonists, CNS anxiolytic effects

Nabilone (Cesamet) 1 to 2 mg orally every 12 hours

Dronabinol (Marinol) 5 to 10 mg orally, rectally, or under the tongue every six to eight hours

Marijuana (only where legal for medical use)

Corticosteroids

Anti-inflammatory, reduces tumor-related swelling centrally or peripherally

Dexamethasone 2 to 8 mg orally or IV every four to eight hours

Dopamine receptor blockers

Benzamides

Peripheral (more than central) dopamine D2 receptor blocker, with some 5-HT antagonism and cholinergic stimulation at bowel level improving gastric emptying and increasing lower esophageal sphincter tone

Metoclopramide (Reglan) 5 to 20 mg orally or IV every six hours as needed

Butyrophenones

Central (more than peripheral) dopamine D2 receptor blocker, with antimuscarinic activity

Haloperidol (formerly Haldol) 0.5 to 2 mg orally or IV every four to eight hours

Droperidol 1.25 to 2.5 mg IV (one to three doses)

Phenothiazines

Dopamine D2 receptor blocker, with some antimuscarinic and antihistaminic activity

Prochlorperazine (formerly Compazine) 5 to 10 mg orally or IV every six to eight hours; or 25 mg rectally every 12 hours

Chlorpromazine 12.5 to 25 mg IV every six to eight hours; or 25 to 50 mg orally every eight hours


5-HT = 5-hydroxytryptamine; CNS = central nervous system; IV = intravenously.

Information from reference 34.

DELIRIUM AND THE “DEATH RATTLE”

Up to 85 percent of patients experience delirium in the last weeks of life, up to 46 percent with agitation.36 It manifests as a sudden onset of worsened mental status with agitation. This distressing symptom often occurs in those with rapidly escalating opioid requirements and can be challenging for all. Prevention can be undertaken in all patients at risk by providing continuity of care; keeping familiar persons at the bedside; limiting medication, room, and staff changes; limiting unnecessary catheterization; and avoiding restraints. Causes such as polypharmacy, opioid toxicity, urinary retention, constipation, and infection should be ruled out. For mild to moderate cases, add haloperidol.37 More severe terminal delirium can be managed with midazolam infusion or other forms of sedation. These interventions, which in conjunction with high-dose opioids can induce “double effect” (the outcome of hastening death when the intention is purely to relieve symptoms), require expertise and can lead to ethical controversy.38,39 Consultation with a palliative care specialist is recommended when delirium, pain, or any other symptoms appear to be intractable.

Table 4

Choice of Antiemetic Based on Cause of Nausea and Vomiting

Cause of nausea and vomiting Antiemetic

Anxiety, anticipatory, psychologic

Benzodiazepines, canniboids

Bowel obstruction

Octreotide (Sandostatin; see text)

Gastroparesis

Metoclopramide (Reglan)

Increased intracranial pressure, central nervous system pain

Dexamethasone

Inner ear dysfunction (rare in palliative care)

Anticholinergics, antihistamines

Medication (primarily chemotherapy)

5-HT3 and dopamine receptor blockers

Metabolic (e.g., uremia, cirrhosis)

5-HT3 and dopamine receptor blockers, antihistamines, steroids

Opioid bowel dysfunction

Methylnaltrexone (Relistor)


5-HT = 5-hydroxytryptamine.

Information from reference 34.

Table 4   Choice of Antiemetic Based on Cause of Nausea and Vomiting

View Table

Table 4

Choice of Antiemetic Based on Cause of Nausea and Vomiting

Cause of nausea and vomiting Antiemetic

Anxiety, anticipatory, psychologic

Benzodiazepines, canniboids

Bowel obstruction

Octreotide (Sandostatin; see text)

Gastroparesis

Metoclopramide (Reglan)

Increased intracranial pressure, central nervous system pain

Dexamethasone

Inner ear dysfunction (rare in palliative care)

Anticholinergics, antihistamines

Medication (primarily chemotherapy)

5-HT3 and dopamine receptor blockers

Metabolic (e.g., uremia, cirrhosis)

5-HT3 and dopamine receptor blockers, antihistamines, steroids

Opioid bowel dysfunction

Methylnaltrexone (Relistor)


5-HT = 5-hydroxytryptamine.

Information from reference 34.

As mental status changes occur during the dying process, patients lose the capacity to clear upper respiratory secretions (“death rattle”). Nonpharmacologic interventions, such as positioning to facilitate drainage and very gentle anterior suctioning (not deep), are an appropriate initial response. Pharmacologic interventions may include hyoscyamine (Levsin), glycopyrrolate (Robinul), scopolamine, octreotide, and the oral use of atropine eyedrops (Table 5).40 Patients do not report experiencing these sounds to be as distressing as family members or caregivers find them, and education regarding this issue may be as effective as positioning and medication.41 A randomized trial is presently underway comparing the effectiveness of different strategies.

Table 5

Treatment of Excessive Respiratory Secretions

Treatment Dosage

Atropine eye drops 1%

One to two drops orally or under the tongue; titrate every eight hours

Glycopyrrolate (Robunil)

1 mg orally or 0.2 mg subcutaneously or intravenously every four to eight hours as needed

Hyoscyamine (Levsin)

0.125 to 0.5 mg orally, under the tongue, subcutaneously, or intravenously every four hours as needed

Scopolamine

One to two patches applied topically and changed every 48 to 72 hours


Information from reference 40.

Table 5   Treatment of Excessive Respiratory Secretions

View Table

Table 5

Treatment of Excessive Respiratory Secretions

Treatment Dosage

Atropine eye drops 1%

One to two drops orally or under the tongue; titrate every eight hours

Glycopyrrolate (Robunil)

1 mg orally or 0.2 mg subcutaneously or intravenously every four to eight hours as needed

Hyoscyamine (Levsin)

0.125 to 0.5 mg orally, under the tongue, subcutaneously, or intravenously every four hours as needed

Scopolamine

One to two patches applied topically and changed every 48 to 72 hours


Information from reference 40.

Final Comment

The end of life is a sacred time in every human culture, a final opportunity to promote and experience spiritual growth. However, spiritual work is difficult, if not impossible, when in pain, when short of breath, or when in a wet bed. Family physicians who care for patients at the end of life have a profound influence on the quality of patients' lives and the dying experience for families. There is always something more that can be done for comfort, no matter how dire a situation appears to be. Palliative care can provide an environment of comfort, healing, and affirmation near the end of life, something that is deeply appreciated by patients and their families, as well as the entire health care team.

The Authors

PATRICK L. CLARY, MD, is medical director of Exeter (N.H.) Hospital's palliative care service; Rockingham Visiting Nurse Association and Hospice in Exeter, N.H.; and Riverside Rest Home in Dover, N.H. He received his medical degree from Georgetown University in Washington, DC, and completed a family medicine residency at Brookdale University Hospital and Medical Center in Brooklyn, NY. Dr. Clary is the author of Dying for Beginners.

PHILIP LAWSON, MD, ABHPM, is an adjunct associate professor at Dart-mouth College in Hanover, N.H., and a family physician with Ammonoosuc Community Health Services, Littleton, N.H. He also leads the Palliative Care Team at Littleton Regional Hospital. Dr. Lawson received his medical degree from the University of Calgary, Alberta, Canada, and completed a residency at the Northwestern Ontario Rural Family Medicine Program in Thunder Bay, Ontario, Canada.

Address correspondence to Patrick L. Clary, MD, 550 Lincoln Ave., Portsmouth, NH 03891 (e-mail: plclary@aol.com). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

1. Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice from the American College of Physicians. Ann Intern Med. 2008;148(2):141–146.

2. Lorenz KA, Lynn J, Dy SM, et al. Evidence for improving palliative care at the end of life: a systematic review. Ann Intern Med. 2008;148(2):147–159.

3. Morrison LJ, Morrison RS. Palliative care and pain management. Med Clin North Am. 2006;90(5):983–1004.

4. von Gunten CF. Interventions to manage symptoms at the end of life. J Palliat Med. 2005;8(suppl 1):S88–S94.

5. Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer. Arch Intern Med. 2000;160(6):786–794.

6. Jennings AL, Davies AN, Higgins JP, Broadley K. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev. . 2001;(4):CD002066.

7. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnea. BMJ. 2003;327(7414):523–528.

8. Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev. 2008;(2): CD005623.

9. Krulewitch H, London MR, Skakel VJ, Lunstedt GJ, Thomason H, Brammel-Smith K. Assessment of pain in cognitively impaired older adults: a comparison of pain assessment tools and their use by nonprofessional caregivers. J Am Geriatr Soc. 2000;48(12):1607–1611.

10. Warden V, Hurley AC, Volicer I. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):9–15.

11. Portenoy RK, Sibirceva U, Smout R, et al. Opioid use and survival at the end of life. J Pain Symp Man. 2006;32(6):532–540.

12. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin. JAMA. 2005;293(24):3043–3052.

13. New Hampshire Hospice and Palliative Care Center. Opioid use guidelines. http://www.nhhpco.org/opioid.htm. Accessed April 23, 2009.

14. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed. Glenview, Ill.: American Pain Society; 2003.

15. Bradshaw M, Sen A. Use of a prophylactic antiemetic with morphine in acute pain: randomised controlled trial. Emerg Med J. 2006;23(3):210–213.

16. Herndon CM, Jackson KC II, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy. 2002;22(2):240–250.

17. Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer. 1995;3(2):135–138.

18. Hallenbeck J. Fast fact and concept #15. Constipation. August 2005. 2nd ed. End-of-Life/Palliative Education Resouce Center. http://www.eperc.mcw.edu/fastFACT/ff_015.htm. Accessed April 23, 2009.

19. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A suppl):11S–18S.

20. Miles CL, Fellowes D, Goodman ML, Wilkinson S. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2006;(4):CD003448.

21. Stephen AM, Cummings JH. The microbial contribution to human faecal mass. J Med Microbiol. 1980;13(1):45–56.

22. McNicol ED, Boyce D, Schumann R, Carr DB. Muopioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008;(2):CD006332.

23. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–2343.

24. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35(5):458–468.

25. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence based report. J Clin Oncol. 2001;19(9):2542–2554.

26. Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician. 2007;10(3):493–500.

27. Kripke BJ, Finck AJ, Shah NK, Snow JC. Naloxone antagonism after narcotic-supplemented anesthesia. Anesth Analg. 1976;55(6):800–805.

28. Jatoi A, Podratz KC, Gill P, Hartmann LC. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer. J Support Oncol. 2004;2(4):323–334.

29. Dunn GP. Palliating patients who have unresectable colorectal cancer: creating the right framework and salient symptom management. Surg Clin North Am. 2006;86(4):1065–1092.

30. Krouse RS, McCahill LE, Easson AM, Dunn GP. When the sun can set on an unoperated bowel obstruction: management of malignant bowel obstruction. J Am Coll Surg. 2002;195(1):117–128.

31. Feuer DJ, Broadley KE, Shepherd JH, Barton DP. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;(3):CD002764.

32. Ouellette J, Patterson L, Termuhlen P. Fast fact and concept #91. Interventional options for upper GI obstruction. December 2007. 2nd ed. End-of-Life/Palliative Education Resource Center. http://www.eperc.mcw.edu/fastFact/ff_091.htm. Accessed April 23, 2009.

33. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;(3):CD001219.

34. Markowitz AJ, Rabow MW. Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time… nothing was working”. JAMA. 2008;299(15):1826.

35. Büttner M, Walder B, von Elm E, Tramèr MR. Is low-dose haloperidol a useful antiemetic?: A meta-analysis of published and unpublished randomized trials. Anesthesiology. 2004;101(6):1454–1463.

36. Breitbart W, Alici Y. Agitated and delirium at the end of life: “We could manage him”. JAMA. 2008;300(24):2898–2910.

37. Jackson KC, Lipman AG. Drug therapy for delirium in terminally ill patients. Cochrane Database Syst Rev. 2004;(2):CD004770.

38. Lo B, Rubenfeld G. Palliative sedation in dying patients: “we turn to it when everything else hasn't worked”. JAMA. 2005;294(14):1810–1816.

39. Boyle J. Medical ethics and double effect: the case of terminal sedation. Theor Med Bioeth. 2004;25(1):51–60.

40. Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev. 2008;(1):CD005177.

41. Wilders H, Menten J. Death rattle: prevalence, prevention, and treatment. J Pain Symptom Manage. 2002;23(4):310–317.


Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article